Trintellix®
vortioxetine

PrTRINTELLIX® IS INDICATED FOR THE TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD) IN ADULTS.[1]

COVERED by most private insurance plans AND PUBLIC FORMULARIES ACROSS CANADA (restrictions may apply)[2*]

37.5 MILLION patients treated WORLDWIDE with Trintellix for up to 3 months[3†]

TRINTELLIX

- Convenient, once-daily dosing[1]
- May be taken with or without food[1]

5 mg

Decrease to a minimum of **5 mg** once daily may be considered for patients who do not tolerate higher doses.[1]

STARTING AND RECOMMENDED DOSE

10 mg

10 mg once daily **in patients <65 years of age**[1]

20 mg

Depending on individual patient response, the dose may be increased to a maximum of **20 mg** once daily, as tolerated.[1]

- **5 mg once daily starting dose in patients of 65 years of age or older**[1]
  - Caution is advised when treating elderly patients with doses >10 mg/day due to the limited efficacy and safety data from patients of 65 years of age or older that were treated with these doses in controlled clinical trials.

For more information about Trintellix and its dosing options, go to **Trintellix.ca/dosing**.

* Trintellix is eligible for reimbursement by Non-Insured Health Benefits, Veteran Affairs Canada and Correctional Service Canada, and for formulary coverage in the following provinces and territories: Quebec, Ontario, Alberta, Manitoba, Saskatchewan, New Brunswick, Newfoundland and Labrador, Nova Scotia, Prince Edward Island Northwest Territories, Yukon and British Columbia (special authorization). Refer to provincial formularies for more information.

† Estimation based on internal data.

Trintellix®
vortioxetine

Clinical use:

Efficacy in providing symptomatic relief of MDD demonstrated in trials of up to 8 weeks' duration; efficacy in maintaining an antidepressant response demonstrated for up to 24 weeks.

Physicians who elect to use Trintellix for extended periods should periodically re-evaluate the usefulness of the drug for individual patients.

The lowest effective dose of 5 mg/day should always be used as the starting dose in elderly patients ≥65 years of age.

Not indicated in patients <18 years of age.

Contraindication:

- Combined use with monoamine oxidase inhibitors (MAOIs)

Most serious warnings and precautions:

- **Potential association with behavioural and emotional changes, including self-harm:** Severe agitation-type events reported; rigorous clinical monitoring for suicidal ideation or other indicators of potential for suicidal behaviour is advised in patients of all ages; this includes monitoring for agitation-type emotional and behavioural changes.
- **Discontinuation symptoms:** Gradual reduction in dose, rather than abrupt cessation, is recommended.

Other relevant warnings and precautions:

- Dependence/tolerance
- Caution when driving or operating machinery
- Abnormal bleeding
- Potential for increased risk of postpartum hemorrhage
- Caution in moderate or severe hepatic impairment
- Bone fracture risk
- Caution in patients who have a history of seizures or in patients with unstable epilepsy
- Serotonin syndrome/neuroleptic malignant syndrome
- Cognitive and motor disturbances
- Angle-closure glaucoma
- Caution in patients with a history of mania/hypomania and discontinue use in any patient entering a manic phase
- Aggression/Agitation
- Caution with concurrent use of electroconvulsive therapy (ECT)
- Hyponatremia
- Caution in patients with severe renal insufficiency
- Not recommended during breastfeeding
- Dosage adjustment in elderly patients

For more information:

Consult the Product Monograph at www.trintellixmonograph.ca for important information about contraindications, warnings, precautions, adverse reactions, interactions, dosing instructions and conditions of clinical use not discussed in this piece.

The Product Monograph is also available by calling 1-800-586-2325.

References: 1. Trintellix Product Monograph. Lundbeck Canada Inc., August 4, 2021. **2.** Data on file: Trintellix Coverage Canada. Lundbeck. December 2021. **3.** Data on file. Lundbeck Canada Inc. February 2022.

VRT-B-100033-E-V3